Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2010

View Archived Issues

IntraCellular Therapies claims new PDE 1 inhibitors

Roche discloses novel PDE 10A inhibitors

Exelixis patents S1P1 receptor agonists for autoimmune diseases

Merck & Co. and Mochida claim new coagulation factor IXa inhibitors

Phase III data released on tanezumab in knee osteoarthritis pain

SB-1518 dose selected for phase II evaluation in myelofibrosis

Interim phase II data reported on ENB-0040 in childhood hypophosphatasia

Pooled phase III data show efficacy of tesamorelin in HIV-related lipodystrophy

Pilot trial finds XOMA-052 beneficial in uveitis of Behcet's disease

TroVax to be evaluated in mesothelioma in phase I/II trial

CHMP recommends approval of Shire's VPRIV for type 1 GD

Gilead signs definitive agreement to acquire CGI Pharmaceuticals

AstraZeneca and MMV join to identify antimalaria candidates

CHMP recommends approval of Sycrest for bipolar disorder

Revlimid approved in Japan for relapsed or refractory multiple myeloma

Pfizer suspends osteoarthritis program for tanezumab

MorphoSys and Xencor collaborate on mAb for B-cell malignancies

FDA sets new decision date for motavizumab BLA

Basilea presents update on phase III isavuconazole program

CHMP confirms previous negative opinion for ceftobiprole

CHMP recommends approval of vernakalant for atrial fibrillation

Pariet approved in Japan for nonerosive GERD

Galderma discloses new tyrosinase inhibitors

Corcept nears enrollment completion in phase III Corlux trial

EMA's CHMP issues positive opinion for Pharming's Rhucin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...